Morningstar Investment Management LLC Acquires 9,270 Shares of Pfizer Inc. $PFE

Morningstar Investment Management LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 19.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 57,082 shares of the biopharmaceutical company’s stock after purchasing an additional 9,270 shares during the period. Morningstar Investment Management LLC’s holdings in Pfizer were worth $1,384,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in PFE. Brighton Jones LLC grew its holdings in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Pfizer by 69.0% in the first quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company’s stock valued at $1,600,000 after acquiring an additional 25,785 shares during the last quarter. Elevation Point Wealth Partners LLC boosted its holdings in Pfizer by 15.9% in the first quarter. Elevation Point Wealth Partners LLC now owns 16,809 shares of the biopharmaceutical company’s stock valued at $426,000 after acquiring an additional 2,311 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Pfizer by 55.3% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 2,606,123 shares of the biopharmaceutical company’s stock valued at $66,039,000 after acquiring an additional 928,180 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on PFE shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Bank of America raised their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Morgan Stanley decreased their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average target price of $28.35.

Pfizer Price Performance

Shares of PFE opened at $24.72 on Tuesday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.82. The stock has a market cap of $140.52 billion, a P/E ratio of 13.15, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The stock’s 50-day moving average price is $24.88 and its two-hundred day moving average price is $24.12.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the business earned $0.60 earnings per share. The company’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.